Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etoricoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 20/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.97 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoricoxib SCHEMBL30988052 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL14163961 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL29366203 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL4680 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL29402456 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL321747 | 0.97 | PTGS2 (0.97) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL183950 | 0.97 | PTGS2 (0.97) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL14126237 | 0.97 | PTGS2 (0.97) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL28893910 | 0.97 | PTGS2 (0.97) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL28319282 | 0.96 | PTGS2 (0.95) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773618-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ETORICOXIB AND POLYMORPHS THEREOF | Cadila Healthcare Limited (IN) | 2014-09-10 | — | — | EP | claimed |
| WO-2013105106-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ETORICOXIB AND POLYMORPHS THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2013-07-18 | — | — | WO | claimed |
| US-20040029921-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. | 2004-02-12 | — | — | US | claimed |
| EP-0912518-B1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-09-10 | — | — | EP | claimed |
| US-20030065011-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. | 2003-04-03 | — | — | US | claimed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | claimed |
| EP-0912518-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-05-06 | — | — | EP | claimed |
| US-5861419-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; ETORICOXIB PATENT | MERCK FROSST CANAD, INC. (CA) | 1999-01-19 | — | — | US | claimed |
| WO-1998003484-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-01-29 | — | — | WO | claimed |
| EP-2773618-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ETORICOXIB AND POLYMORPHS THEREOF | Cadila Healthcare Limited (IN) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013105106-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ETORICOXIB AND POLYMORPHS THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2013-07-18 | — | — | WO | disclosed |
| WO-2012004677-A1 | SOLID STATE FORMS OF ETORICOXIB SALTS | ACTAVIS GROUP PTC EHF (IS) | 2012-01-12 | — | — | WO | disclosed |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | CARDAX PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| EP-1890729-A2 | USE OF CAROTENOIDS AND/OR CAROTENOID DERIVATIVES/ANALOGS FOR REDUCTION/INHIBITION OF CERTAIN NEGATIVE EFFECTS OF COX INHIBITORS | Cardax Pharmaceuticals, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2001062252-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6071936-A | ANTIINFLAMMATORY AGENTS ANTIPYRETICS, ANALGESICS, ANTICARCINOGENIC AGENTS, SIDE EFFECT REDUCTION | MERCK FROSST CANADA & CO. (CA) | 2000-06-06 | — | — | US | disclosed |
| US-6001843-A | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK & CO., INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0912518-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-05-06 | — | — | EP | disclosed |
| US-5861419-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; ETORICOXIB PATENT | MERCK FROSST CANAD, INC. (CA) | 1999-01-19 | — | — | US | disclosed |
| WO-1998003484-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | PTGS2 14/4885PTGS1 20/4885ABCC4 3154/4885 |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | LPL, ALOX12, LCLAT1 | PTGS2 9/4885PTGS1 26/4885ABCC4 1599/4885 |
| US-20030065011-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885ABCC4 1696/4885 |
| US-20040029921-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885ABCC4 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.